Melius Pharma is a Swedish clinical stage pharmaceutical company. We develop treatments for severe diseases with high unmet clinical needs at a reduced development risk.
Supported by exploratory cough data in several indications, Melius Pharma is developing ME-015 (suplatast tosilate) as a first in class, safe and well tolerated oral treatment for chronic cough in idiopathic pulmonary fibrosis (IPF) patients.
ME-015 is a new chemical entity in all geographies outside of Japan where it has been on the market for over 25 years for different indications with a very good safety profile.
Clinicaltrial.gov entry for our first clinical trial COSMIC-IPF: https://clinicaltrials.gov/study/NCT05983471
Watch a 2-minute video on cough related to Idiopathic Pulmonary Fibrosis and ME-015's mechanism of action here: https://vimeo.com/811293278
Company Details
- Employees
- 5
- Founded
- 2021
- Address
- Stockholmsvägen 45c, Stocksund,se-18278,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.meliuspharma.com/
- Keywords
- INNATE PHARMACEUTICALS AB.
- HQ
- Stocksund
Melius Pharma Questions
Melius Pharma's website is https://www.meliuspharma.com/
Melius Pharma's LinkedIn profile is https://se.linkedin.com/company/melius-pharma
Melius Pharma has
5 employees.
View email and phone details for 5
employees at Melius Pharma.
Melius Pharma's industry is
Biotechnology Research
Melius Pharma's top competitors are
Innate Pharmaceuticals Ab,
Osher V'chedvah Ab,
Starget Pharma,
Medlius Pharma,
Biotech-Igg,
Tvardi Therapeutics,
United Therapeutics Corporation,
Oncozenge Ab,
Trevi Therapeutics, Inc.,
Eribis Pharmaceuticals.
Melius Pharma's categories are Biotechnology Research
Melius Pharma's founding year is 2021
